X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs NOVARTIS - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA NOVARTIS CIPLA/
NOVARTIS
 
P/E (TTM) x 44.5 390.5 11.4% View Chart
P/BV x 3.9 19.2 20.2% View Chart
Dividend Yield % 0.3 1.5 22.0%  

Financials

 CIPLA   NOVARTIS
EQUITY SHARE DATA
    CIPLA
Mar-17
NOVARTIS
Mar-16
CIPLA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs622982 63.3%   
Low Rs458556 82.4%   
Sales per share (Unadj.) Rs181.9252.9 71.9%  
Earnings per share (Unadj.) Rs12.962.1 20.7%  
Cash flow per share (Unadj.) Rs29.363.3 46.3%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.41.3 28.5%  
Book value per share (Unadj.) Rs155.7363.6 42.8%  
Shares outstanding (eoy) m804.5131.96 2,517.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.0 97.7%   
Avg P/E ratio x42.012.4 339.1%  
P/CF ratio (eoy) x18.412.2 151.6%  
Price / Book Value ratio x3.52.1 164.0%  
Dividend payout %15.516.1 96.6%   
Avg Mkt Cap Rs m434,51624,580 1,767.7%   
No. of employees `00023.00.8 3,064.2%   
Total wages/salary Rs m26,3381,801 1,462.3%   
Avg. sales/employee Rs Th6,349.110,748.9 59.1%   
Avg. wages/employee Rs Th1,143.02,395.2 47.7%   
Avg. net profit/employee Rs Th449.32,641.1 17.0%   
INCOME DATA
Net Sales Rs m146,3028,083 1,810.0%  
Other income Rs m2,287829 275.7%   
Total revenues Rs m148,5898,913 1,667.2%   
Gross profit Rs m24,758234 10,571.3%  
Depreciation Rs m13,22937 36,047.1%   
Interest Rs m1,5942 88,544.4%   
Profit before tax Rs m12,2221,025 1,192.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-7017 -418.6%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m1,798752 239.0%   
Profit after tax Rs m10,3541,986 521.3%  
Gross profit margin %16.92.9 584.1%  
Effective tax rate %14.773.4 20.0%   
Net profit margin %7.124.6 28.8%  
BALANCE SHEET DATA
Current assets Rs m87,37012,678 689.2%   
Current liabilities Rs m33,0812,433 1,359.7%   
Net working cap to sales %37.1126.7 29.3%  
Current ratio x2.65.2 50.7%  
Inventory Days Days8733 266.0%  
Debtors Days Days6222 277.1%  
Net fixed assets Rs m111,56769 161,224.3%   
Share capital Rs m1,609160 1,006.9%   
"Free" reserves Rs m123,64511,460 1,078.9%   
Net worth Rs m125,25411,621 1,077.8%   
Long term debt Rs m36,4540-   
Total assets Rs m209,53214,400 1,455.1%  
Interest coverage x8.7570.5 1.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.6 124.4%   
Return on assets %5.713.8 41.3%  
Return on equity %8.317.1 48.4%  
Return on capital %8.523.6 36.1%  
Exports to sales %34.20.7 4,593.4%   
Imports to sales %8.318.6 44.9%   
Exports (fob) Rs m50,05060 83,139.0%   
Imports (cif) Rs m12,2031,503 812.1%   
Fx inflow Rs m51,066186 27,410.8%   
Fx outflow Rs m17,6781,821 970.9%   
Net fx Rs m33,388-1,635 -2,042.7%   
CASH FLOW
From Operations Rs m23,8242,531 941.3%  
From Investments Rs m-13,127-8,270 158.7%  
From Financial Activity Rs m-13,239-386 3,432.3%  
Net Cashflow Rs m-2,478-6,125 40.5%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 2.0 610.0%  
FIIs % 23.7 1.6 1,481.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 21.5 121.9%  
Shareholders   161,166 41,647 387.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Infosys & Axis Bank Top Gainers(01:30 pm)

After opening the day in green, the Indian share markets have continued the momentum and are presently trading on a strong note.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 17, 2018 03:03 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS